GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation

Journal of Clinical Investigation

Volumn 125, Issue 12, 2015, Pages 4714-4728

  Shigeto, Makoto ^a,b,c   Ramracheya, Reshma ^a   Tarasov, Andrei I ^a,d   Cha, Chae Young ^a,b   Chibalina, Margarita V ^a   Hastoy, Benoit ^a   Philippaert, Koenraad ^e   Reinbothe, Thomas ^b   Rorsman, Nils ^a,f   Salehi, Albert ^b   Sones, William R ^a   Vergari, Elisa ^a   Weston, Cathryn ^g   Gorelik, Julia ^h   Katsura, Masashi ^c   Nikolaev, Viacheslav O ⁱ   Vennekens, Rudi ^e   Zaccolo, Manuela ^f   Galione, Antony ^f   Johnson, Paul R V ^a,d   Kaku, Kohei ^c   Ladds, Graham ^g,j   Rorsman, Patrik ^a,b,d   more..

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^e LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY OF WARWICK   (United Kingdom)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; DIACYLGLYCEROL; ENZYME INHIBITOR; GLUCAGON LIKE PEPTIDE 1; INSULIN; ISRADIPINE; PROTEIN KINASE C; SODIUM ION; THAPSIGARGIN; TOLBUTAMIDE; TRANSIENT RECEPTOR POTENTIAL CHANNEL M4; TRANSIENT RECEPTOR POTENTIAL CHANNEL M5; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; TRPM4 PROTEIN, HUMAN; TRPM4 PROTEIN, MOUSE; TRPM5 PROTEIN, HUMAN; TRPM5 PROTEIN, MOUSE;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DEPOLARIZATION; EC50; ELECTRIC ACTIVITY; ENZYME ACTIVATION; FEMALE; INSULIN RELEASE; MALE; MEMBRANE DEPOLARIZATION; MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; ANIMAL; CYTOLOGY; DRUG EFFECTS; GENETICS; HUMAN; ION TRANSPORT; KNOCKOUT MOUSE; METABOLISM; SECRETION (PROCESS);

ANIMALS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ION TRANSPORT; MEMBRANE POTENTIALS; MICE; MICE, KNOCKOUT; PROTEIN KINASE C; TETRADECANOYLPHORBOL ACETATE; TRPM CATION CHANNELS;

EID: 84948843973     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81975     Document Type: Article

References (63)

1. Danaei G, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31-40.
2. Weir GC, Bonner-Weir S. Islet β cell mass in diabetes and how it relates to function, birth, and death. Ann N Y Acad Sci. 2013;1281:92-105.
3. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047-2058.
4. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11):1788-1803.
5. Balas B, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92(4):1249-1255.
6. Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007;21(4):517-533.
7. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Gluca-gon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol. 1997;273(4 pt 1):G920-G927.
8. Luque MA, et al. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol. 2002;173(3):465-473.
9. Lopez-Delgado MI, Morales M, Villanueva-Penacarrillo ML, Malaisse WJ, Valverde I. Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats. Endocrinology. 1998;139(6):2811-2817.
10. Villanueva-Penacarrillo ML, Marquez L, Gonzalez N, Diaz-Miguel M, Valverde I. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res. 2001;33(2):73-77.
11. Valverde I, Merida E, Delgado E, Trapote MA, Villanueva-Penacarrillo ML. Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue. Endocrinology. 1993;132(1):75-79.
12. Fridolf T, Ahren B. GLP-1(7-36) amide stimulates insulin secretion in rat islets: studies on the mode of action. Diabetes Res. 1991;16(4):185-191.
13. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes. 2002;51(suppl 3):S434-S442.
14. Gromada J, Brock B, Schmitz O, Rorsman P. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol. 2004;95(6):252-262.
15. Doyle ME, Egan JM. Mechanisms of action of glu-cagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007;113(3):546-593.
16. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. 2000;49(11):1751-1760.
17. Goke R, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268(26):19650-19655.
18. Knudsen LB, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664-1669.
19. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
20. Bavec A, Hallbrink M, Langel U, Zorko M. Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling. Regul Pept. 2003;111(1-3):137-144.
21. Hallbrink M, Holmqvist T, Olsson M, Ostenson CG, Efendic S, Langel U. Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galpha(s) and Galpha(i)/Galpha(o) activation. Biochim Biophys Acta. 2001;1546(1):79-86.
22. Montrose-Rafizadeh C, et al. Pancreatic gluca-gon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology. 1999;140(3):1132-1140.
23. -/- mice. Proc Natl Acad Sci USA. 2010;107(11):5208-5213.
24. Holz GGt, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature. 1993;361(6410):362-365.
25. + current properties in islet α-and β-cells reflect cell-specific Scn3a and Scn9a expression. J Physiol. 2014;592(pt 21):4677-4696.
26. Gromada J, Ding WG, Barg S, Renstrom E, Rors-man P. Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glu-cagon-like peptide 1 and glucagon act via distinct receptors. Pflugers Arch. 1997;434(5):515-524.
27. Nikolaev VO, Bunemann M, Hein L, Han-nawacker A, Lohse MJ. Novel single chain cAMP sensors for receptor-induced signal propagation. J Biol Chem. 2004;279(36):37215-37218.
28. Allen MD, Zhang J. Subcellular dynamics of protein kinase A activity visualized by FRET-based reporters. Biochem Biophys Res Commun. 2006;348(2):716-721.
29. 2+-dependent activation of phospholipase C in insulin-secreting cells. J Biol Chem. 2006;281(39):28499-28507.
30. Rozengurt E. Protein kinase D signaling: multiple biological functions in health and disease. Physiology. 2011;26(1):23-33.
31. Gao ZY, Gilon P, Henquin JC. The role of protein kinase-C in signal transduction through vasopressin and acetylcholine receptors in pancreatic B-cells from normal mouse. Endocrinology. 1994;135(1):191-199.
32. 2+ and diacylglycerol signaling in living cells. PLoS One. 2012;7(8):e42791.
33. Weston C, Poyner D, Patel V, Dowell S, Ladds G. Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast. Br J Pharmacol. 2014;171(15):3651-3665.
34. 2+ buffering and electrical activity in mouse pancreatic β-cells. Biophys J. 1999;76(4):2018-2028.
35. Rorsman P, Eliasson L, Kanno T, Zhang Q, Gopel S. Electrophysiology of pancreatic β-cells in intact mouse islets of Langerhans. Prog Biophys Mol Biol. 2011;107(2):224-235.
36. Low JT, et al. Glucose principally regulates insulin secretion in mouse islets by controlling the numbers of granule fusion events per cell. Diabetologia. 2013;56(12):2629-2637.
37. 2+ signal that is essential for insulin secretion in mouse pancreatic islets. Diabetes. 2008;57(4):868-878.
38. 2+ signaling in the pancreatic β-cell. Islets. 2010;2(5):323-330.
39. Sumara G, et al. Regulation of PKD by the MAPK p38Δ in insulin secretion and glucose homeostasis. Cell. 2009;136(2):235-248.
40. Fridolf T, Ahren B. GLP-1(7-36)amide-stimulated insulin secretion in rat islets is sodium-dependent. Biochem Biophys Res Commun. 1991;179(1):701-706.
41. Kato M, Ma HT, Tatemoto K. GLP-1 depolarizes the rat pancreatic beta cell in a Na(+)-dependent manner. Regul Pept. 1996;62(1):23-27.
42. 2+-activated cation channel TRPM4. J Biol Chem. 2003;278(33):30813-30820.
43. Vennekens R, Nilius B. Insights into TRPM4 function, regulation and physiological role. Handb Exp Pharmacol. 2007;(179):269-285.
44. Liman ER. TRPM5 and taste transduction. Handb Exp Pharmacol. 2007;(179):287-298.
45. Toft-Nielsen MB, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-3723.
46. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999;140(11) 5356-5363.
47. Gefel D, Hendrick GK, Mojsov S, Habener J, Weir GC. Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3', 5'-monophosphate formation. Endocrinology. 1990;126(4):2164-2168.
48. Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FP. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch Biochem Biophys. 2004;428(2):136-143.
49. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia. 2005;48(4):612-615.
50. Gromada J, et al. Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting beta TC3-cells by enhancement of intracellular calcium mobilization. Diabetes. 1995;44(7):767-774.
51. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K. Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway J Pharmacol Sci. 2008;108(3):274-279.
52. Rickels MR, Mueller R, Markmann JF, Naji A. Effect of glucagon-like peptide-1 on p-and a-cell function in isolated islet and whole pancreas transplant recipients. J Clin Endocrinol Metab. 2009;94(1):181-189.
53. Vennekens R, et al. Increased IgE-dependent mast cell activation and anaphylactic responses in mice lacking the calcium-activated nonse-lective cation channel TRPM4. Nat Immunol. 2007;8(3):312-320.
54. Ruas M, et al. TPC1 has two variant isoforms, and their removal has different effects on endo-lysosomal functions compared to loss of TPC2. Mol Cell Biol. 2014;34(21):3981-3992.
55. Calcraft PJ, et al. NAADP mobilizes calcium from acidic organelles through two-pore channels. Nature. 2009;459(7246):596-600.
56. Lake SP, et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes. 1989;38(suppl 1):143-145.
57. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37(4):413-420.
58. Ammala C, Ashcroft FM, Rorsman P. Calcium-independent potentiation of insulin release by cyclic AMP in single β-cells. Nature. 1993;363(6427):356-358.
59. Ammala C, Eliasson L, Bokvist K, Larsson O, Ashcroft FM, Rorsman P. Exocytosis elicited by action potentials and voltage-clamp calcium currents in individual mouse pancreatic B-cells. J Physiol. 1993;472:665-688.
60. Braun M, et al. Voltage-gated ion channels in human pancreatic β-cells: electrophysiological characterization and role in insulin secretion. Diabetes. 2008;57(6):1618-1628.
61. Gopel SO, et al. Activation of Ca(2+)-dependent K(+) channels contributes to rhythmic firing of action potentials in mouse pancreatic β cells. J Gen Phys iol. 1999;114(6):759-770.
62. Girard CA, et al. Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic β cells recapitulates neonatal diabetes. J Clin Invest. 2009;119(1):80-90.
63. Reinbothe TM, Safi F, Axelsson AS, Mollet IG, Rosengren AH. Optogenetic control of insulin secretion in intact pancreatic islets with β-cell-specific expression of Channelrhodopsin-2. Islets. 2014;6(1):e28095.